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Molecular genetic analysis of severe coagulation
factor XI deficiency in six Italian patients
Factor XI (FXI) is a zymogen of a serineprotease that participates in the earlyphase of blood coagulation as a catalyst
in the conversion of factor IX (FIX) to acti-
vated FIX (FIXa) in the presence of calcium
ions.1,2 FXI exists in two different forms: plas-
ma FXI, a glycoprotein primarily produced
by hepatocytes3 (molecular weight between
125 and 160 kDa) and platelet FXI (a 220-
kDa product), whose site of synthesis and
nature are still matters of debate.4
Among coagulation factors, human FXI is
unique in that it is a dimer composed of two
identical 80-kDa polypeptide chains linked
by a disulfide bond, and circulates in plasma
as a complex with high molecular weight
kininogen (HMWK).5 Upon activation, each
monomer is cleaved into an amino-terminal
heavy chain and a carboxy-terminal light
chain, held together by three disulfide
bonds.6 Each light chain contains the cat-
alytic domain of the enzyme and is homol-
ogous to the trypsin family of serine pro-
teases. Each heavy chain, which mediates
binding to HMWK and FIX, is composed of
four tandem repeats of 90 or 91 amino acids
(apple domains) with a characteristic disul-
fide-bonded organized structure.7 The FXI
gene (F11), located on the tip of the long
arm of chromosome 4 (4q35.2),8 consists of
15 exons and 14 introns (named A to N)
spread over a genomic region of approxi-
mately 23 kb.9
FXI deficiency was first reported as a
hemophilia-like syndrome by Rosenthal and
co-workers in 1953.10 However, this coagu-
lopathy differs from classical hemophilia in
that spontaneous bleedings, such as
hemarthrosis and purpura, are rare and
hemorrhages most often occur only after
Background and Objectives. Factor XI (FXI) deficiency is a rare autosomal recessive
coagulopathy which is, however, frequent among Ashkenazi Jews. Two mutations, type II
(Glu117stop) and type III (Phe283Leu), account for the majority of abnormal alleles in this
population. The aim of this study was to analyze the molecular basis of FXI deficiency in
six unrelated Italian probands with severe deficiency, a population hitherto largely unex-
plored.
Design and Methods. All patients showed unmeasurable functional FXI levels in plas-
ma. Mutational screening was performed by sequencing. Haplotype analysis was per-
formed using intragenic polymorphisms. Expression studies were performed by transient
transfection in COS-1 cells.
Results. Sequencing identified two novel mutations: a nonsense mutation (Cys118stop)
in exon 5 in two probands, and a 6-bp deletion (643-648delATCGAC) in exon 7 in one
proband. The Cys118stop is predicted to cause FXI deficiency by a secretion defect and/or
by increased mRNA degradation. The 6-bp deletion causes the loss of residues Ile197 and
Asp198. There was a remarkable secretion impairment of the deleted FXI protein. In four
of the six probands, the type II mutation was found. Haplotype analysis in patients car-
rying the type II mutation revealed that they share a common haplotype, perhaps derived
from a Jewish ancestor. 
Interpretation and Conclusions. The identification and characterization of two novel
mutations widen the mutational spectrum of FXI deficiency. Haplotype analysis is com-
patible with a Jewish origin of the type II mutation. The high occurrence of the type II
mutation among Italian patients will be helpful to direct future genetic screenings.
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trauma or minor surgery. Moreover, since it is inherited
as an autosomal recessive trait (MIM *264900), both
sexes can be affected. Homozygotes have severe FXI
deficiency (less than 20%), whereas heterozygotes have
partial FXI deficiency (20 to 50%).11 Curiously, bleeding
manifestations, which may range from a complete lack
of symptoms to hemorrhages requiring blood transfu-
sions, seem to correlate poorly with the level of plasma
FXI activity. It has been hypothesized that platelet FXI
(probably originating from an alternative splicing), may
help to compensate for the absence of plasma FXI in
asymptomatic individuals.12 Another reasonable expla-
nation for this paradox is that the one-stage FXI activ-
ity assay used does not reflect some effects of FXI that
are crucial for hemostasis, such as those on the func-
tion of platelets and of the fibrinolytic system;13 how-
ever this explanation does not account for the vast
majority of FXI-deficient patients, who are antigen neg-
ative. 
Very recently, dominant transmission of FXI deficien-
cy was described in two families. This unusual pattern
of inheritance was due to two different missense muta-
tions which were demonstrated to exert a dominant
negative effect on wild type FXI secretion through intra-
cellular heterodimer formation.14
FXI deficiency is a rare disorder in the general popu-
lation (estimated incidence of 1 in 106),15,16 however it is
one of the most common inherited disorders among
Ashkenazi Jews. Two prevalent mutations (the so-called
type II and type III mutations) have been identified in
the FXI gene of Ashkenazi Jewish patients.17-19 The type
II mutation is a nonsense mutation in exon 5, creating
a premature termination codon (Glu117stop) while the
type III mutation is a missense mutation in exon 9
resulting in a Phe283Leu amino acid substitution. Type
II and type III mutations together account for most cas-
es (95%) of FXI deficiency in Ashkenazi Jews, but are
responsible for only 12% of cases of FXI deficiency in
patients with no known Jewish ancestry.20,21 Among the
latter, a significantly higher level of allelic heterogene-
ity has been reported in different ethnic groups, remark-
able exceptions being French Basques, French patients
from Nantes and English patients, in whom different
prevalent ancestral mutations were found.22-24 So far,
besides the type II and type III mutations, 56 addition-
al causative mutations (31 missense mutations, 10 non-
sense mutations, 7 splice-site mutations, 7 small inser-
tion/deletion, and a single large deletion) have been
found throughout the gene in both Ashkenazi Jews and
in other populations.14,22-43
The aim of the present work was to identify the
molecular basis of FXI deficiency in six unrelated Ital-
ian probands. 
Design and Methods
Patients
Six probands with severe FXI deficiency, belonging to
apparently unrelated families (as far as ascertainable
from their personal history) were studied.
Proband 1 is a 36-year-old man from Milan. At the
age of 23 years he was treated with fresh-frozen plas-
ma infusions after cervical disc surgery; subsequently,
he was treated with an antifibrinolytic drug after a den-
tal extraction. No bleeding problems occurred after
either operative procedure. Other family members had
no bleeding tendency, except for the proband’s sister
who experienced excessive bleeding after tonsillectomy,
at the age of 2 years, and had a FXI activity level in plas-
ma < 1%.
Proband 2 is a 56-year old woman from Milan. She
had normal menses and no bleeding tendency until the
age of 24 years when a bleeding episode occurred after
a dental extraction. This did not, however, require any
transfusions. Subsequently, at the age of 52 years, she
underwent a right knee arthroscopy under prophylac-
tic treatment with fresh-frozen virus-inactivated plas-
ma. More recently, prophylactic treatment was not
administered to cover a further minor orthopedic pro-
cedure, and no bleeding complications occurred. 
Proband 3 is a 62-year old man from Reggio Emilia.
He frequently suffered from severe epistaxis, resolved by
fresh-frozen plasma infusion. Excessive bleeding
occurred after dental extractions and as a consequence
of surgery.
Proband 4 is a 33-year old man from Reggio Emilia.
No specific clinical data, except for ecchymoses,
hematomas, and post-traumatic bleeding tendency,
suggestive of a coagulation disorder, could be obtained.
His 37-year-old brother also had severely reduced FXI
levels in plasma (FXI antigen, 2%).
Proband 5 is a 30-year old man from Milan. He has a
thalassemia trait. He has not shown any bleeding man-
ifestations: no severe bleeding problems occurred after
a car accident or dental extractions. Recently, he suc-
cessfully underwent varicocele repair under prophylac-
tic treatment with fresh-frozen virus-inactivated plas-
ma. No bleeding tendency was reported for the remain-
ing family members, except for a prolonged partial
thromboplastin time (PTT) in the proband’s sister, who
also had FXI deficiency (FXI activity level, <1%; FXI anti-
gen, unmeasurable). 
Proband 6 is a 16-year old girl from Milan. She first
came to medical attention at the age of 10 years
because of a prolonged PTT found prior to a tonsillec-
tomy. The diagnosis of severe FXI deficiency (FXI coag-
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ulant activity <1%) was made on this occasion. During
childhood and puberty she had recurrent episodes of
epistaxis and suffered from diffuse ecchymoses.
Materials
pCDNA3/FXI expression plasmid, containing the full-
length FXI complementary DNA (cDNA), was kindly pro-
vided by Dr A. Zivelin (Institute of Thrombosis and
Hemostasis, the Chaim Sheba Medical Center, Tel-
Hashomer, Israel). Oligonucleotides were purchased
from Invitrogen (Carlsbad, CA, USA). REDTaq and BIO-
Taq DNA polymerases were from Sigma (St Luis, MO,
USA) and Bioline (London, UK), respectively.
Blood collection and genomic DNA extraction
This study was approved by the Institutional Review
Board of the University of Milan. After acquiring
informed consent, blood samples from all individuals
were collected for biochemical and genetic analyses.
Peripheral venous blood was collected in 1:10 volume of
0.11 M trisodium citrate, pH 7.3. Plasma was obtained
by centrifugation at 2000 g for 10 min and aliquots were
stored at -80°C until use. Genomic DNA was extracted
from whole blood using the Nucleon BACC1 Kit (Amer-
sham Pharmacia Biotech, Uppsala, Sweden). 
Coagulation tests
FXI coagulant activity (FXI:C) was measured by a one-
stage method based on a modified partial thromboplas-
tin time using a lyophilized immunodepleted human
plasma deficient of FXI (Hemoliance, Salt Lake City, UT,
USA). FXI antigen (FXI:Ag) was assayed by an in-house
enzyme-linked immunosorbent assay (ELISA) based on
goat anti-human FXI polyclonal antibodies and peroxi-
dase-conjugated IgG (Affinity Biological Inc., Hamilton,
Ontario, Canada). FXI levels were expressed in both tests
as percentages of pooled normal plasma from 30 nor-
mal male and female individuals. The detection limits of
the FXI functional and immunologic assays were 1%
and 0.1%, respectively. 
Polymerase chain reaction (PCR)
and DNA sequencing
PCR were performed on 200 ng of genomic DNA in a
standard volume of 50 µL. The reaction mixture con-
tained 1× reaction buffer (10 mM Tris [tris (hydrox-
ymethyl) aminomethane]-HCl, pH 8.3, 50 mM KCl,
0.01% gelatin), 1.5 mM MgCl2, 0.4 µM of each primer,
200 µM deoxynucleoside triphosphates and 1.25 U RED-
Taq DNA polymerase (Sigma). The PCR were carried out
on a PTC-100 thermal cycler (MJ-Research, Watertown,
MA, USA) under standard conditions. Primers were
designed on the basis of the known genomic sequence
of F11 (Ensembl accession number ENSG0000088926).
Primer sequences, as well as the specific PCR conditions
for each primer couple, are available on request.
Sequencing reactions were performed directly on PCR
products purified by ammonium acetate precipitation.
Sequence analysis was carried out on both strands by
means of the BigDye Terminator Cycle Sequencing kit
and an automated ABI-3100 DNA sequencer (Applied
Biosystems, Foster City, CA, USA). Factura and Sequence
Navigator software packages (Applied Biosystems) were
used for mutation detection.
Haplotype analysis
Two single nucleotide polymorphisms (SNPs), one in
intron A (-231C>T) and one in intron E (HhaI polymor-
phism), and two dinucleotide repeat polymorphisms,
one in intron B (CA)8-13 and one in intron M (AT)7-11 of F11
were analyzed.44-46 Polymorphisms in introns A, E, and B
were genotyped by sequencing the relevant PCR prod-
uct. The microsatellite marker in intron M was PCR-
amplified using a 6-Fam-labeled primer. Labeled prod-
ucts were separated on an ABI-3100 genetic analyzer
(Applied Biosystems) and analyzed by the GeneScan
software (Applied Biosystems). Oligonucleotide primers
and PCR conditions are listed in Table 1.
Expression of the FXI-∆197-198 mutant protein
The pCDNA3/FXI plasmid was used as a template to
obtain a mutant vector expressing a FXI protein lack-
G. Zadra et al.
Table 1. Oligonucleotide primers used in F11 haplotype analysis.
Primer Sequence Location Annealing temperature
(intron) (°C)
FXI-ex1-F 5’ GCAAATACGCCTTGAAATGC 3’ 5’UTR 55
FXI-IVS2-R 5’ TTGCAGTGTGATTTCCCTCT 3’ B
FXI-IVS2-F 5’ FamAAGTAGTGAACACAGCCTCC 3’ B 56
FXI-IVS2-R2 5’ TTTCCACCTGTAATCCCAGC 3’ B
FXI-IVS5-F 5’ GTAAGAAGGACTTAGCCA 3’ E 53
FXI-IVS5-R 5’ CACATGAAGAAGGAGAGTG 3’ E
FXI-IVS13-F 5’ GATAATCGCTTGAACTTGGG 3’ M 55
FXI-IVS14-R 5’ CCCCAACGCATTAAGCATTC 3’ M
UTR: untranslated region; Fam: 6-carboxyfluorescein; F: forward; R: reverse.
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ing amino acids Ile197 and Asp198 (pCDNA3/FXI-∆197-
198). The deletion was created by a slight modification
of the QuickChange Site-Directed Mutagenesis Kit pro-
tocol. The mutagenic oligonucleotides used to intro-
duce the ∆197-198 deletion were FXIdel(ID)-F (5’-
CGGTGTTTGCAGACAGCAACAGTGTCATGGCTCCCGATGC-
3’) and FXIdel(ID)-R (5’-GCATCGGGAGCCATGACACT-
GTTGCTGTCTGCAAACACCG-3’). The modification of the
original protocol consisted in the use of 40-mer primers,
bridging the deletion, which ensured stable annealing
on both sides of the deleted region.
The deleted plasmid was checked by sequencing.
pCDNA3/FXI and pCDNA3/FXI-∆197-198 were extract-
ed by the EndoFree Plasmid Maxi Kit (Sigma). African
green monkey kidney COS-1 cells were cultured in Dul-
becco’s modified Eagle’s Medium (DMEM) supplement-
ed with 10% fetal bovine serum, antibiotics (100 IU/mL
penicillin and 100 µg/mL streptomycin) and glutamine
(1%), and grown at 37°C in a humidified atmosphere of
5% CO2, and 95% air, according to standard procedures.
In each transfection experiment equal numbers of cells
were transiently transfected with LIPOFECTAMINE 2000
reagent (Invitrogen) in 6-well plates, with pCDNA3/FXI
or with pCDNA3/FXI-∆197-198 or with equimolar
amounts of both plasmids, essentially as described by
the manufacturer. Twenty-nine hours after transfec-
tion, cells were washed twice with phosphate-buffered
saline (PBS) and cultured for additional 48 hours in
serum-free medium supplemented with glutamine,
antibiotics, 5 mM CaCl2, and 5 mg/mL bovine serum
albumin.
For each transfection (performed twice in duplicate)
a mock experiment, with the unrelated pUC18 plasmid
as a negative control, was set up. 
FXI antigen measurement in conditioned media
and in cell lysates
FXI antigen levels were evaluated by ELISA, as
described above, both in conditioned media and in cell
lysates. Standard curves were constructed with refer-
ence plasma diluted 1:100 to 1:6400 in Tris-buffered
saline (50 mM Tris, 150 mM NaCl), pH 7.5. Conditioned
media were collected in pre-chilled tubes containing a
protease inhibitor mixture (Complete; Roche, Basel,
Switzerland), centrifuged to remove cell debris, and
stored at -80°C until use. To obtain cell lysates, cells
were washed three times with pre-chilled PBS and lysed
for 1 hour on ice with lysis buffer containing 1× PBS,
1.5% Triton X-100, and 1× Complete.47 Cell lysates were
centrifuged to remove cell debris. FXI activity was
measured in about 10x concentrated medium as
described above (see coagulation tests). Media were
concentrated by Centricon Plus-20 centrifugal filters,
containing a cellulose membrane with a molecular
weight cut-off of 10 kDa (Millipore, Bedford, MA, USA).
The FXI specific activity (expressed as a percentage)
was calculated as the ratio between FXI:C and FXI:Ag
levels, both measured in concentrated media.
Results
Patients’ data
Six Italian FXI-deficient probands were studied and
their main demographic and clinical characteristics are
summarized in Table 2. All probands had unmeasurable
plasma levels of FXI functional activity and very low
FXI antigen levels (ranging from 0.2 to 5%).
Mutational screening
In all six analyzed probands, mutational screening
was performed by sequencing the whole F11 coding
region, as well as exon-intron boundaries and about
300 bp of the promoter region. Sequencing of F11 iden-
tified two novel mutations. The first one was a C→A
transversion in exon 5 corresponding to cDNA position
408 (numbering according to GenBank accession num-
ber NM000128, starting from the first nucleotide of the
ATG start codon), which causes a nonsense mutation at
amino acid 118 (Cys118stop, numbering omits the sig-
nal peptide). This mutation, found in three patients
(proband 1 and his sister, and proband 6) in the
homozygous state (Figure 1), involves the codon just
downstream of that altered by the type II mutation
(Glu117stop). It is predicted to cause the synthesis of a
protein lacking a portion of the heavy chain and the
Table 2. Characteristics of probands with FXI deficiency.
Probands
Characteristics P1 P2 P3 P4 P5 P6
City of origin Milan Milan Reggio Emilia Reggio Emilia Milan Milan
Gender M F M M M F
Present age, y 36 55 61 32 29 15
FXI activity levels, % <1 <1 <1 <1 <1 <1
FXI antigen levels, % 0.4 0.4 0.2 5 0.5 0.3
Severity of symptoms mild mild moderate moderate asymptomatic mild
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whole light chain (Figure 2). The second newly identi-
fied mutation was an in-frame 6-bp deletion (643-
648delATCGAC) in exon 7 and was found in a com-
pound heterozygous patient (proband 4) (Figure 1). The
643-648delATCGAC mutation causes the loss of amino
acids Ile197 and Asp198 in the third apple domain of the
heavy chain, which contains the binding site for FIX
and platelets (Figure 2). In the remaining patients, the
type II mutation (a G→A transition at cDNA position
403 leading to the Glu117stop mutation),15 widely dif-
fused among FXI-deficient Jews but fairly rare among
non-Jewish patients, was found. 
Figure 1. Novel mutations in
F11 identified in the analyzed
probands. Electropherograms
showing the mutations identi-
fied in probands P1, P6, and P4
(upper panels) and the corre-
sponding wild-type sequences
(lower panels) are reported
over a schematic representa-
tion of F11. The 408C→A
transversion (left), whose
nucleotide position is indicat-
ed by an arrow, was present in
the homozygous state in both
P1 and P2, while the 6-bp dele-
tion (right) was found in the
heterozygous state in P4. The
position of the newly identified
mutations on a schematic rep-
resentation of F11 is also indi-
cated. Exons (approximately to
scale) are represented by box-
es, while introns (not to scale)
are represented by lines.
Figure 2. Amino acid sequence
of FXI showing the position of
the identified mutations
(Glu117stop, Cys118stop,
6 4 3 - 6 4 8 d e l A T C G A C ) .
Schematic representation of
the primary structure of the FXI
molecule showing the presence
of the four apple domains (A1-
A4) at the N-terminus and of
the catalytic domain at the C-
terminus. Disulfide bonds are
also indicated. The mutations,
identified in the six unrelated
Italian probands, are located in
the second (Glu117stop,
Cys118stop) and in the third
apple domain (643-648delATC-
GAC).
Patients P1,P6 Patient P4
408 C>A
643-648delA TC GAC
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Mutant
F11
Wild type
G G G T G G G G G G G
G G G T G C C G G G G
C A T C G A C A G T
C A G T G T C A T G
C A T C G A C A G T
Ca
ta
ly
tic
 d
om
ai
n
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Haplotype analysis
To establish whether or not the probands bearing the
type II mutation share the same haplotype, four intra-
genic polymorphic sites (-231C>T in intron A, (CA)8-13 in
intron B, HhaI polymorphism in intron E, and (AT)7-11 in
intron M) were analyzed. These were previously report-
ed to define a common haplotype shared by all Jewish
FXI-deficient patients carrying the type II mutation.44-46
Genotyping was performed both by sequencing and by
fragment analysis. In particular, analysis of HhaI poly-
morphism, carried out by sequencing, allowed the iden-
tification of the polymorphic nucleotide within the HhaI
restriction site: it is the third of four bp recognized by
HhaI (-431G→A). The G→A substitution prevents the
enzyme from cutting.
In haplotype construction, seven additional SNP, iden-
tified during mutational screening, were included: -
138A→C in intron A, 430T→C in exon 5, -361C→T in
intron E, 801A>G in exon 8, 1191T→C in exon 11,
1812G→T and 1839G→A in exon 15. For each muta-
tion, haplotype analysis revealed a founder effect (Table
3). In particular, the type II mutation segregates with
the same haplotype [-231C, (CA)11, -431G (HhaI), (AT)9]
previously reported in Ashkenazi, Iraqi, Yemenite, Syri-
an, and Marrocan Jewish patients carrying the type II
mutation, demonstrating that the mutation was of the
same ancestry.46
The Cys118stop mutation was associated with the
same haplotype in both probands 1 and 6, suggesting
a common origin also for this mutation. This haplotype
differs from the type II mutation haplotype at each ana-
lyzed marker, except for the AT repeat in intron M and
for three SNP (one in exon 5 and two in exon 15).
Proband 4, who is a compound heterozygote for the
type II and the novel 643-648 delATCGAC mutations,
resulted homozygous for all markers except for the -
231C→T and 430T→C polymorphisms in intron A and
exon 5, respectively. The presence of a T and a C at
markers -231C→T and 430T→C therefore defines a
new haplotype associated with the 6-bp deletion. 
Expression of wild-type and ∆197-198
recombinant FXI in COS-1 cells
To evaluate whether the deletion of Ile197 and Asp198
affects FXI secretion, the mutant FXI-∆197-198 protein
was expressed in COS-1 cells. To this purpose, deletion
mutagenesis was performed on the pCDNA/FXI plasmid
to produce the pCDNA3/FXI-∆197-198 vector, using a
modification of the QuickChange protocol, as described
in the Design and Methods. Following transient trans-
fection with either pCDNA3/FXI or pCDNA3/FXI-∆197-
198 or with equimolar amounts of both expression plas-
mids (to mimic the heterozygous condition), serum-free
conditioned media and cell extracts were analyzed for
the presence of FXI antigen by ELISA. 
In media conditioned by cells expressing FXI-∆197-
198, FXI antigen levels were reduced to 17% of the wild
type, demonstrating a remarkable impairment of FXI
secretion (Figure 3A). Co-transfection with equimolar
amounts of wild-type and mutant FXI-expressing plas-
mids partially restored extracellular FXI antigen (to
about 63% of the wild type) (Figure 3A). In cell lysates,
no significant difference was observed between the
wild-type and mutant FXI antigen levels (Figure 3A).
FXI coagulant specific activity was measured on con-
centrated conditioned media by an assay based on
Table 3. F11 haplotype of probands with FXI deficiency.
Probands
Marker Location P1 P2 P3 P4 P5 P6
#Nucleotide positions of the intronic polymorphisms have been numbered starting from the nearest splicing junction. cNumbering refers to the amino acid sequence omitting
the signal peptide. @Numbering refers to the cDNA sequence (GenBank, accession number NM000128), starting from the first nucleotide of the ATG start codon.
The “Jewish” haplotype is represented in gray boxes, other polymorphisms are indicated in white boxes. The mutations (bold) found in the six analyzed probands are repre-
sented in the corresponding position within F11 haplotypes as black boxes.
intron A
intron A
intron B
exon 5
exon 5
exon 5
intron E
intron E
exon 7
exon 8
exon 11
intron M
exon 15
exon 15
-231C>T#
-138A>C#
(CA)n
Glu117stopc (type-II)@
Cys118stopc
430T>C*
-431G>A (HhaI)
-361C>T#
643648delATCGAC*
801A>G+
1191T>C*
(AT)n
1812G>T*
1839G>A*
T T
C C
9 9
− −
+ +
T T
A A
T T
− −
A A
T T
9 9
G G
G G
C C
A A
11 11
+ +
− −
T T
G G
C C
− −
G G
C C
9 9
G G
G G
C C
A A
11 11
+ +
− −
T T
G G
C C
− −
G G
C C
9 9
G G
G G
C T
A A
11 11
+ −
− −
T C
G G
C C
− +
G G
C C
9 9
G G
G G
C C
A A
11 11
+ +
− −
T T
G G
C C
− − 
G G
C C
9 9
G G
G G
T T
C C
9 9
− −
+ +
T T
A A
T T
− − 
A A
T T
9 9
G G
G G
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thromboplastin time, and the results are reported in
Figure 3B. The activity of the FXI-∆197-198 mutant
protein was below the detection limit of the assay
(<1%), even after 10-fold concentration of conditioned
media. FXI molecules secreted by cells co-expressing
wild-type and mutant cDNA had a specific activity sim-
ilar to the wild-type recombinant FXI. To exclude pos-
sible artefacts caused by the concentration step, the
coagulant activity of the wild-type recombinant FXI
was also measured in conditioned medium as such. The
calculated specific activity resulted in good agreement
with data obtained from the concentrated medium
(data not shown).
Discussion
To our knowledge, only two Italian FXI-deficient
patients have so far been analyzed,29,35 therefore this
represents the first study exploring the molecular basis
of severe FXI deficiency in a cohort of six unrelated
Italian probands.
Both functional and antigen levels of FXI were
markedly reduced in all analyzed patients, confirming
the diagnosis of quantitative FXI deficiency. All
patients had mild symptoms such as epistaxis and
excessive oozing after dental extractions; only two of
them required fresh-frozen plasma treatment after
surgical procedures. Sequencing of F11 identified two
novel mutations: a nonsense mutation (Cys118stop)
in exon 5 in two homozygous probands and an in-
frame 6-bp deletion (643-648delATCGAC) in exon 7 in
a compound heterozygous proband. The Cys118stop
mutation involves the codon immediately downstream
of that altered by the type II mutation. The truncation
at residue 118 is predicted to cause the synthesis of a
protein lacking the third and fourth apple domains of
the heavy chain (involved in the binding of FXI to FIX
and in the dimerization process, respectively)48 and the
whole light chain (containing the catalytic domain).
The virtual absence of FXI protein truncated at residue
Cys118 in blood may be due to a secretion defect of
the truncated protein, which might be recognized as
abnormal by the quality control system of secretory
proteins, a stringent mechanism that prevents the
secretion of misfolded and incompletely assembled
proteins.49
Moreover, since premature termination codons are
known to frequently affect the metabolism of the cor-
responding mRNAs, transcripts carrying the
Cys118stop mutation might be committed to degra-
dation by the nonsense mRNA-mediated decay. This
surveillance mechanism, which efficiently degrades
transcripts carrying premature termination codons,
protects organisms from the deleterious dominant
negative or gain of function effects of truncated pro-
teins.50 In any case, should the Cys118stop FXI be
expressed, the resulting protein would be completely
non-functional, since it would lack the domains
responsible for binding to FIX, dimerization and cat-
alytic activity of FXI.
The in-frame 6-bp deletion was identified in a com-
pound heterozygous proband, who also carried the
type II mutation. The finding of a three-nucleotide
repeat (ACA) located at the 5’ and 3’ ends of the delet-
ed fragment might explain the 6-bp deletion by slip-
page and mispairing at the replication fork during DNA
synthesis.51 This mutation causes the loss of amino
acids Ile197 and Asp198 in the third apple domain of the
heavy chain, leading to FXI deficiency presumably by
altering the proper folding of the third apple domain
and consequently impairing FXI secretion. Expression
of a recombinant deleted FXI in COS-1 cells enabled
the demonstration of the effect of Ile197 and Asp198
removal on protein secretion. In media conditioned by
G. Zadra et al.
Figure 3. Transient expression of wild-type and mutant
FXI protein in COS-1 cells. pCDNA3/FXI (wild type), pCD-
NA3/FXI-∆197-198 (mutant) or equimolar amounts of
both plasmids (heterozygous condition) were transiently
transfected in COS-1 cells. Equal numbers of cells and
equal amounts of plasmids were used in transfection
experiments, as described in Design and Methods. (A).
Antigen levels of recombinant FXI were measured both in
conditioned media and in the corresponding cell lysates
by an ELISA assay. Bars represent relative concentrations
of protein in media and cell lysates compared to the mean
for wild type FXI (set as 100%). Results are given as
means ± standard deviations. (B). The specific activities
of recombinant proteins were determined by calculating
the ratio between FXI activity (measured by a one-stage
method based on a modified partial thromboplastin time)
and FXI antigen levels, both assayed in about 10x con-
centrated media. Bars represent means ± standard devi-
ation of 4 independent experiments, each performed in
duplicate. The mean value of wild-type FXI was set as
100%; n.c.: not calculable. 
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cells expressing the mutant FXI, antigen levels were
reduced by 83% relative to the wild-type. These
results are suggestive of impaired secretion of the
mutant protein and fit well with the FXI antigen lev-
el measured in the proband’s plasma (5%), which was
significantly higher than that in any of the other ana-
lyzed probands. Co-transfection experiments with
equal amounts of mutant and wild-type expression
plasmids partially corrected the secretion defect (anti-
gen levels in conditioned media rose from 17% to 63%
of the wild type). The intracellular levels of FXI-∆197-
198 (similar to those measured in the wild type) sug-
gest that the secretion defect caused by this two-
amino acid deletion does not cause intracellular accu-
mulation of the mutant protein.
The coagulant activity of secreted wild-type and
mutant FXI was evaluated after concentration of con-
ditioned media. However, the coagulant activity of the
mutant protein was not measurable, whereas the spe-
cific activity calculated from media conditioned by
cells co-expressing the wild-type and the mutant pro-
teins was indistinguishable from the specific activity
of wild-type recombinant FXI. These results demon-
strate that the coagulant activity of recombinant FXI-
∆197-198 is strongly impaired and might explain the
small discrepancy between FXI activity (<1%) and
antigen (5%) levels measured in the plasma of
proband 4. In the remaining patients, the type II muta-
tion, very common in FXI-deficient Jews, was found in
the homozygous state. Previous haplotype studies
revealed that the type II mutation, responsible for the
majority of cases of FXI deficiency in Ashkenazi Jews
but also highly common in Iraqi Jews and frequent in
Sephardic Jews and Arabs, is invariantly associated
with a single haplotype.16,46 Given these findings, it was
speculated that this mutation might have originated
in an ancient Jewish founder approximately 2500
years ago, before the divergence of the major segment
of Jews.16 This mutation, besides being found in Jews,
has also now been reported in non-Jewish individuals
from England52 and Portugal,33 and in both cases it was
associated with the same Jewish haplotype. 
In order to identify the origin of the type II mutation
in the Italian population, a haplotype comprising a
series of 11 polymorphisms (nine biallelic and two
microsatellite markers) spanning the entire F11 was
determined. This analysis revealed that all individuals
carrying the type II mutation shared the same haplotype
found in Jewish patients, thus revealing the Jewish ori-
gin of the mutation also in the Italian patients. The high
frequency of this mutation in the Italian population
suggests that testing for the presence of type II muta-
tion should be the first genetic screening in FXI-defi-
cient patients.
The same polymorphic markers were genotyped in the
two probands bearing the newly identified Cys118stop
mutation, who were found to share an identical haplo-
type (different from that of patients bearing the type II
mutation), thus suggesting a common origin for the
Cys118stop mutation. Screening of a higher number of
FXI-deficient patients will be necessary to reveal the
existence of a founder effect also for this mutation in
the Italian population. 
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